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TRANSLATIONAL RELEVANCE:  While molecular subtyping has helped identify distinct 
breast cancer subtypes, there is no biomarker yet identified that can differentiate those patients 
within subtypes with respect to prognosis.  One of the hallmarks of cancer is the deregulation of 
G1 to S transition of the cell cycle.  Alterations in this checkpoint can serve as an indicator of 
prognosis in many cancers and a potential predictor of poor outcome in breast cancer patients. 
We evaluated the subcellular localization of a key cell cycle regulator (cyclin E) in breast cancer 
specimens from 2,494 patients from 4 different cohorts from multiple institutions with distinct 
clinical and pathological features.  In multivariable analysis we show that cytoplasmic 
expression of cyclin E is associated with the greatest risk of recurrence compared with other 
prognostic factors (including Ki67) across all subtypes and cohorts, providing a rationale for 
investigating treatment strategies that could specifically target tumors with cytoplasmic cyclin E. 
  
ABSTRACT 
Background: Low-molecular-weight-cyclin E (LMW-E) detected by Western blot, predicts for 
reduced breast cancer survival, however, it is impractical for clinical use.  LMW-E lacks a 
nuclear localization signal which leads to accumulation in the cytoplasm that can be detected by 
immunohistochemistry.  We tested the hypothesis that cytoplasmic staining of cyclin E can be 
used as a predictor of poor outcome in different subtypes of breast cancer  using patient cohorts 
with distinct clinical and pathologic features. 
Methods:  We evaluated the subcellular localization of cyclin E in breast cancer specimens from 
2,494 patients from 4 different cohorts:  303 from a prospective study and 2,191 from 
retrospective cohorts (National Cancer Institute [NCI], MD Anderson Cancer Center [MDA] and 
the United Kingdom [UK]). Median follow-up times were 8.0, 10.1, 13.5, and 5.7 years, 
respectively.  
Results:  Subcellular localization of cyclin E on immunohistochemistry was associated with full-
length (nuclear) and low molecular weight isoforms (cytoplasmic) of cyclin E on Western blot 
analysis. In multivariable analysis, cytoplasmic cyclin E staining was associated with the greatest 
risk of recurrence compared with other prognostic factors across all subtypes in three (NCI, 
MDA and UK) of the cohorts.  In the MDA cohort, cytoplasmic cyclin E staining outperformed 
Ki67 and all other variables as prognostic factors. 
Conclusion: Cytoplasmic cyclin E, identifies patients with the highest likelihood of recurrence 
consistently across different patient cohorts and subtypes.  These patients may benefit from 
alternative therapies targeting the oncogenic isoforms of cyclin E.  
 
 
INTRODUCTION 
Overexpression of low molecular weight cyclin E (LMW-E), which was originally 
discovered in breast cancer by our group and subsequently reported by others 1-7, is also found in 
ovarian cancer 8,9, melanoma 10, colorectal cancer 11-14, lung cancer 15, and renal cell carcinoma 
16. LMW-E is generated from N-terminal neutrophil elastase cleavage of the 50-KDa, full-length 
cyclin E1 17. The loss of the NH2 terminus alters the subcellular localization of LMW-E to the 
cytoplasm, which can no longer be degraded by the nuclear FBW-7, resulting in stable and 
functionally active LMW-E in the cytoplasm 18. LMW-E is not found in normal tissues, and it 
causes cell cycle deregulation and resistance to endocrine therapy and chemotherapy 19-22. 
Compared with full-length cyclin E, LMW-E has a higher affinity for binding cyclin-dependent 
kinase 2 (CDK2) and is capable of phosphorylating substrates such as pRb with higher activity 
23. Transgenic mice expressing LMW-E have a higher incidence of mammary tumor 
development and metastasis compared with those expressing full-length cyclin E 24, and 
tumorigenicity is dependent on CDK2 25. 
We previously reported an analysis of 395 patients with breast cancer in which we 
demonstrated that overexpression of LMW-E, as measured by Western blot analysis, is 
associated with distant metastases and reduced overall survival 26. At a median follow-up of 4 
years, 91.7% of patients with overexpression of cyclin E (full-length and LMW-E) according to 
Western blot analysis developed distant metastases, compared with 7% of patients without cyclin 
E overexpression (p < 0.001). In multivariable analysis, total cyclin E expression was an 
independent prognostic variable and a better predictor of both disease-free and overall survival 
than nodal status, estrogen receptor (ER) status, or stage. 
Western blot analysis is impractical for routine clinical use, which has led several groups to 
examine the prognostic value of cyclin E expression measured by immunohistochemistry. In 
these studies, cyclin E expression was scored on the basis of nuclear staining, and no consistent 
association between cyclin E overexpression and reduced survival was demonstrated 27. We 
previously reported that LMW-E is localized predominantly in the cytoplasm, where it binds to 
CDK2 and has greater kinase activity than full-length cyclin E 18. Others have reported that 
mislocalization of other cyclins, including cyclins A, B, and D1, has functional implications in 
tumorigenesis 28-31. These data suggest that examining tumors for expression of cyclins may be 
best assessed by immunohistochemistry to determine location (nuclear versus cytoplasmic) and 
intensity of staining. To test this hypothesis, we recently used separate nuclear and cytoplasmic 
scoring systems for both cyclin E and p-CDK2 expression to demonstrate altered cellular 
accumulation of these proteins using immunohistochemical analysis32. We evaluated 7 different 
cyclin E antibodies to identify the one antibody that can consistently detect cytoplasmic cyclin E 
in a panel of 14 breast cell lines and tumors from cyclin E transgenic mouse models and showed 
that nuclear versus cytoplasmic staining of cyclin E readily differentiated full-length from LMW-
E, respectively. Lastly, we showed that cytoplasmic cyclin E correlated strongly with 
cytoplasmic p-CDK2 (P < 0.0001) in patient samples32.  
In the present study, we tested the hypothesis that expression of LMW-E, as measured by 
cytoplasmic staining of cyclin E in immunohistochemistry, predicts recurrence and survival 
outcomes in patients with breast cancer across diverse large cohorts and subtypes. 
 
 
 
MATERIALS AND METHODS 
Patients and tissue samples 
 Four cohorts were analyzed in the current study (Supplementary Table 1): a prospective 
cohort of 303 patients with stage I-III breast cancer who enrolled in our study between January 
2000 and June 2010 (Lab00-222; approved by The University of Texas MD Anderson Cancer 
Center Institutional Review Board) and 3 retrospective cohorts, including 725 patients with stage 
I-II breast cancer treated at MD Anderson between 1985 and 1999 (MDA) 33, 951 patients with 
stage I-II breast cancer treated at four US hospitals between 1985 and 1997 (NCI) and 515 
elderly patients with stage I-II breast cancer treated at Nottingham University Hospitals, 
Nottingham, England, between 1987 and 2005 (UK).  A complete data-base of all the clinical 
and pathological factors evaluated for all 4 cohorts is provided in Supplemental Table 2. Fresh 
tumor and normal breast tissue was collected during surgery from 152 patients in the Lab00-222 
cohort, and formalin-fixed, paraffin-embedded tissue was available for all patients in all four 
cohorts. REMARK diagram for each cohort is shown in Supplemental Figure 3. 
Western blot analysis 
Fresh tissues from the 152 patients in the prospective cohort were collected and protein 
lysates subjected to western blot using a monoclonal antibody to the C-terminus of cyclin E 
(HE12, Santa Cruz Biotechnology) and actin (Roche) as previously described 26,34 with the 
following modifications. Briefly, 50 µg of protein from each tumor tissue being examined was 
loaded into the lanes of a 10% SDS-PAGE gel and submitted to electrophoresis for 300 volt 
hours. These gels were then transferred to Immobilon P membrane (Millipore) by electrophoresis 
for 400 volt hours at 4°C. The membranes were blocked for 1 hour in BLOTTO (5% nonfat dry 
milk in TBST; 20 mM Tris, 137 mM NaCl, 0.25% Tween, pH 7.6). Following blocking, the 
membranes were incubated in primary antibodies (at a concentration of 0.1 µg/mL) in BLOTTO 
for 3 hours at room temperature. Following incubation with primary antibody, the membranes 
were washed 3 x 20 minutes in TBS-T and then incubated with goat anti-mouse or anti-rabbit 
IgG–horseradish peroxidase-conjugated secondary antibodies (Pierce) at a dilution of 1:3,000 in 
BLOTTO for 1 hour. The membrane was washed 3 x 20 minutes in TBS-T and developed with 
the Renaissance chemiluminescence system (Perkin-Elmer Life Sciences, Inc.). The membranes 
were placed in an autoradiography cassette, exposed to film, and scanned.  Densitometry was 
performed using ImageQuant Total Lab software (Amersham Biosciences), each band 
quantified, and LMW-E bands were added together.  Values of LMW-E and full-length cyclin E 
were normalized against full-length cyclin E in normal tissue.  
Immunohistochemistry 
Slides from all patients within each cohort were stained for cyclin E using C-terminal 
antibody detecting full-length cyclin E and LMW-E (rabbit polyclonal antibody to cyclin E, C-
19, sc-198, Santa Cruz) as recently described 35. Briefly, Sections (5-m-thick) of FFPE breast 
tumor samples were deparaffinized and rehydrated followed by incubation with 3% hydrogen 
peroxide and methanol to block endogenous peroxidase activity and nonspecific protein-protein 
interactions, respectively. Antigen retrieval was carried out with 0.01mM citric acid-based buffer 
at pH 6.0 using a hot plate in a metal container for 15 min before immunostaining. After 1 hour 
blocking for nonspecific staining, the sections were incubated with cyclin E C-19 polyclonal 
antibody.  Antibodies were detected using a VECTASTAIN Elite ABC kit (PK6101 and 
PK6102; Vector Laboratories, Burlingame, CA). Cells positive for cyclin E were visualized 
using the chromogenic substrate 3,3'-diaminobenzidine. Slides were counterstained with 
hematoxylin and mounted. Tumor cell blocks known to highly express LMW-E were included in 
each batch and negative control were prepared by replacing the primary antibody with PBS 
buffer. All washing steps were performed with, first, PBS alone and then PBS with 0.1% Tween.  
Cyclin E scoring was performed by three pathologists blinded to patient outcomes.  
Scores (0=negative, 1=weak staining, 2=moderate staining, and 3=strong staining) were assigned 
for nuclear and cytoplasmic staining according to percentage of cells stained and intensity of 
staining (Supplemental Figure 1) and as described previously 32. Each tumor sample was scored 
separately for nuclear and cytoplasmic cyclin E expression and LMW-E status was assigned as 
follows: LMW-E negative (no staining or just nuclear staining), LMW-E positive (nuclear + 
cytoplasmic or just cytoplasmic staining). 
ER status, progesterone receptor (PR) status, HER2 status (3+ in immunohistochemistry 
or amplified in fluorescence in situ hybridization), and Ki67 status 36 were determined from 
pathology reports for the MD Anderson and UK cohorts. For the NCI cohort, we stained tissue 
samples for ER, PR, and HER2; fluorescence in situ hybridization was performed at Quintiles 
(Westmont, IL). Samples were collected prior to the change in American Society of Clinical 
Oncology/College of American Pathologists guidelines for ER reporting 37 therefore we 
considered >10% staining on immunohistochemistry to be positive for ER and PR. 
 
Assignment of breast cancer subtype 
 ER, PR, and HER2 were used to approximate breast cancer subtypes. ER- and/or PR-
positive and HER2-negative samples were considered hormone receptor-positive breast cancer; 
HER2-positive (independent of ER and PR status) was considered HER2-positive breast cancer; 
and ER-, PR-, and HER2-negative samples were considered triple-negative breast cancer 
(Supplementary Table 1). 
 Statistical analysis 
Logistic regression was performed to determine whether full-length cyclin E and LMW-E 
expression as detected by Western blot analysis were associated with nuclear and cytoplasmic 
staining for cyclin E in immunohistochemistry. Differences in the cohorts were evaluated using 
chi-square tests for categorical variables and one-way analysis of variance for Ki67. Endpoints 
were overall survival and breast cancer freedom from recurrence (FFR) calculated from the time 
of diagnosis to recurrence. FFR is a modification from the recurrence-free survival endpoint 
from the Hudis et al guidelines 38 and was calculated as the time between the date of diagnosis  
and the date of first recurrence (locoregional or distant) or last follow-up (if no recurrence). FFR 
captures only recurrences and does not include deaths as events, regardless of cause of death. 
Patients who did not experience the endpoint were censored at last follow-up. 
Median follow-up times were computed using the reverse Kaplan-Meier estimator 39.  
The Kaplan-Meier method was used to calculate five-year FFR for each factor. The differences 
in survival curves were evaluated using log-rank test. Univariable and multivariable regression 
analyses were performed using Cox proportional hazards model. The final multivariable Cox 
models were selected using backward elimination procedure by Akaike’s information criterion 
(AIC), which takes into account how well the model fits the data as well as the complexity of a 
model, thereby reducing the risk of overfitting. Model performance was quantified using 
concordance index (C-index) 40, which is a measure of the probability of agreement between 
what the model predicts and the actual observed risk of breast cancer recurrence. The variable 
importance in a model is evaluated using the likelihood ratio test (LRT). Statistical analyses were 
performed using R version 3.2.3 with library survival and rms. R markdown files described for 
each cohort are presented in Supplementary R files 1-4. Each R code includes the definitions of 
FFR, and covariates used for each cohort, including subtype and cyclin E. The multivariable 
Cox-proportional hazards models for each cohort were initially fit with the following covariates: 
age, T stage, Nodal status, Tumor grade, Subtype, Chemotherapy, Radiation therapy, Endocrine 
therapy, and cyclin E. Next, backward elimination procedure was performed for variable 
selection. These files also include calculations of c-indices and provide codes to draw 
monograms. 
 
RESULTS 
Patient characteristics 
There were 2,494 patients with complete data available: 303 from Lab00-222, 725 from 
MDA, 951 from NCI, and 515 from UK. Clinical and pathologic variables for individual cohorts 
and the combined cohort are summarized in Table 1. The cohorts were distinct (P < 0.001) with 
respect to all variables examined except for cytoplasmic cyclin E staining. Patients in the UK 
cohort were older than in other cohorts (median 76 years compared with 53-62 years; P < 
0.0001). Additionally, T stage, nodal status, tumor grade, and subtypes were significantly 
different among the cohorts (P < 0.0001). Treatment variables (chemotherapy, radiation therapy, 
and endocrine therapy) were also significantly distinct among cohorts (P < 0.0001). In the UK 
cohort, not all patients received chemotherapy. These results show that although the four cohorts 
were distinct in all biomarkers examined, they converged with respect to cytoplasmic cyclin E 
staining, suggesting that cytoplasmic cyclin E may be an independent biomarker in these 
patients. 
 
Levels of full-length cyclin E and LMW-E 
Tumor lysates from the 152 patients from the Lab00-222 cohort were subjected to both 
Western blot analysis and immunohistochemistry with the cyclin E antibody. Nuclear and 
cytoplasmic staining of cyclin E were quantified and compared with results from the Western 
blot analysis. Tumors with undetectable or low levels of LMW-E in the Western blot analysis 
showed predominantly nuclear cyclin E staining, whereas tumors with high levels of LMW-E in 
the Western blot analysis demonstrated intense, homogeneous cytoplasmic cyclin E staining 
(Figure 1A). Logistic regression analyses were performed to determine whether LMW-E and 
full-length cyclin E expression in the Western blot analysis were associated with cytoplasmic 
and nuclear staining for cyclin E as a comprehensive score (% positive nuclei × staining 
intensity). Full-length cyclin E expression in Western blot analysis was an independent predictor 
of nuclear cyclin E staining, and LMW-E expression in Western blot analysis was an 
independent predictor of cytoplasmic cyclin E staining (Figure 1A). Thus, assessment of nuclear 
and cytoplasmic cyclin E staining in immunohistochemistry allowed separation into LMW-E 
(cytoplasmic) negative and LMW-E positive groups (Figures 1B, Supplemental Figures 1 and 2). 
 
FFR and overall survival as a function of cyclin E staining 
Median follow-up for the Lab00-222 cohort was 9.8 years (95% confidence interval [CI] 
9.4-10.5 years), 17.9 years (95% CI 17.4-18.6 years) for the MDA cohort, 14.8 years (95% CI 
14.3-15.4 years) for the NCI cohort, and 6.3 years (95% CI 6.1-7.1 years) for the UK cohort. In 
the combined cohort, 981 patients (39.3%) had negative cytoplasmic cyclin E staining and 1,513 
(60.7%) had positive cytoplasmic cyclin E staining, and the distributions did not differ across the 
four cohorts (Table 1).  
In the univariable Cox proportional hazards model, the association between cytoplasmic 
cyclin E staining and FFR was significant (P < 0.01) for all four cohorts (Table 2). The 5-year 
FFR rates for the positive cytoplasmic cyclin E staining groups compared with the negative 
cytoplasmic cyclin E staining groups were 86% compared with 97% for the Lab00-222 cohort, 
74% compared with 93% for the MDA cohort, 69% compared with 93% for the NCI cohort, and 
64% compared with 92% for the UK cohort (Supplemental Table 3). The hazard ratio for a 
patient with positive cytoplasmic cyclin E staining compared with a patient with negative 
cytoplasmic cyclin E staining was 4.16 for the Lab00-222 cohort, 3.19 for the MDA cohort, 4.16 
for the NCI cohort, and 5.01 for the UK cohort (Table 2).  
Kaplan-Meier FFR plots for all four cohorts and all three subtype combinations as a 
function of cytoplasmic cyclin E staining are shown in Figure 2. Positive cytoplasmic cyclin E 
staining was strongly associated with decreased FFR in all four cohorts and across all three 
subtype combinations, except for HER2-positive and triple-negative subtypes in the Lab00-222 
cohort. The associations between cytoplasmic cyclin E staining and FFR were most striking in 
the hormone receptor-positive subtype.  
 
Multivariable analysis 
Clinical and treatment-related factors were represented by the following covariates: age, 
T stage, nodal status, tumor grade, subtype, chemotherapy, radiation therapy, and endocrine 
therapy. The multivariable Cox proportional hazards model was fitted in a dataset corresponding 
to each of the four cohorts. For these analyses, all eight clinical and treatment-related factors and 
cyclin E staining were initially included in the model as potential risk factors. We sequentially 
eliminated factors that provided decreased Akaike information criterion values to obtain the final 
models. The results of the multivariable analysis are displayed in Table 3 and the corresponding 
nomograms are displayed in Figure 3A-D.  
Cytoplasmic cyclin E staining was selected in all the four cohorts, and positive 
cytoplasmic cyclin E staining was strongly associated with poor outcome: FFR hazard ratios 
were 3.19 (P = 0.012) in the Lab00-222 cohort, 2.48 (P < 0.0001) in the MDA cohort, 3.26 (P < 
0.0001) in the NCI cohort, and 6.58 (P < 0.0001) in the UK cohort. In the Lab00-222 cohort, T 
stage, nodal status, subtype, and chemotherapy were selected along with cytoplasmic cyclin E 
staining, and T stage was the most significant predictor for FFR (Table 3 and Figure 3A). In the 
MDA cohort, although age, T stage, nodal status, chemotherapy, and endocrine therapy were 
selected along with cytoplasmic cyclin E staining, the effect of cytoplasmic cyclin E staining was 
the strongest among these factors (Table 3 and Figure 3B). In the NCI cohort, T stage, nodal 
status, tumor grade, and chemotherapy were selected along with cytoplasmic cyclin E staining; 
cytoplasmic cyclin E staining had the strongest effect on FFR (Table 3 and Figure 3C). Lastly, in 
the UK cohort, age, T stage, nodal status, and endocrine therapy were included in the final 
model; cytoplasmic cyclin E staining had the strongest effect on FFR (Table 3 and Figure 3D). 
Figure 3F displays concordance indices for the final models (red) and the final models without 
cytoplasmic cyclin E staining for all four cohorts. The concordance indices showed substantial 
gains when cytoplasmic cyclin E staining was added to the model for all cohorts, especially the 
UK cohort, which had the largest gain.  
 
Significance of cytoplasmic cyclin E staining from the clinical model with Ki67 
Next, we sought to determine whether cyclin E had similar prognostic power using the clinical 
model with Ki67. Information about Ki67 was available for 692 patients in the MDA cohort. 
Median Ki67 expression was 15% and ranged from 0% to 90%. According to the univariable 
Cox proportional hazards model, Ki67 was not significant, with a hazard ratio for a one-unit 
change of 1.005 (95% CI 0.998-1.013). In the multivariable analysis, the backward elimination 
procedure started from the model including Ki67, cytoplasmic cyclin E staining and other 
clinical factors, including age, T stage, nodal status, tumor grade, subtype, chemotherapy, 
radiation therapy, and endocrine therapy. The final model included both Ki67 and cytoplasmic 
cyclin E with other clinical factors, age, T stage, nodal status, chemotherapy, and endocrine 
therapy. Supplemental Table 4 shows the results of the final model and the corresponding 
nomogram is displayed in Figure 3E. The hazard ratio of positive cytoplasmic cyclin E staining 
compared with negative cytoplasmic cyclin E staining was 2.67 (P < 0.0001) and Ki67 was not 
significant at significance level 0.05 (Supplemental Table 4). Cytoplasmic cyclin E staining 
outperformed Ki67 and all other clinical factors with the highest LRT statistics with p-value 
<0.0001 (Supplemental Table 3). The nomogram shown in Figure 3E demonstrates that the 
prognostic power of cyclin E remained the same as in the model without Ki67 in Figure 3B for 
the MDA cohort. 
 
DISCUSSION 
In the current study, we examined the relationship between survival outcomes and LMW-
E as measured by Western blot analysis and immunohistochemistry in patients with breast 
cancer. We found that LMW-E expression in Western blot analysis correlated with cytoplasmic 
cyclin E staining in immunohistochemistry. Cytoplasmic cyclin E staining was associated with 
reduced breast cancer FFR and overall survival in multivariable analysis in four different patient 
cohorts and across all breast cancer subtypes. In our study, patients with breast cancer whose 
tumors had no cytoplasmic cyclin E staining had an overall favorable prognosis, and those with 
any cytoplasmic cyclin E staining had a poor prognosis. 
A number of investigators have examined the prognostic value of cyclin E in breast 
cancer. A meta-analysis of 2534 patients from 12 studies demonstrated that cyclin E 
overexpression was associated with a 2.32-fold increased risk of recurrence in univariate analysis 
and a 1.72-fold increased risk of recurrence in multivariable analysis 41. However, an attempt to 
validate the association between cyclin E overexpression and poor survival in patients enrolled in 
the Southwest Oncology Group 9313 trial using immunohistochemistry for cyclin E on formalin-
fixed, paraffin-embedded tissue did not reveal significantly worse outcomes with overexpression 
of cyclin E 27. We previously reported that LMW-E, not full-length cyclin E, is most active in 
phosphorylating substrates and that LMW-E has a higher affinity than full-length cyclin E for 
binding CDK 42. LMW-E is more tumorigenic in transgenic mouse models, and patients whose 
tumors expressed LMW-E, as measured by Western blot analysis, were shown to be at the 
highest risk for recurrence and death due to breast cancer 24,26,43,44. Because LMW-E lacks the 
nuclear localization signal of full-length cyclin E, we previously investigated the subcellular 
localization of LMW-E and reported that LMW-E accumulates in the cytoplasm, where it binds 
to CDK2 and retains kinase activity 18. This difference in localization could explain why studies 
have shown disparate results with respect to cyclin E overexpression and survival. 
Key issues in the evaluation of tumor markers for clinical use are utility, magnitude, and 
reproducibility 45. The clinical utility of cyclin E as a novel tumor marker is multifaceted. In 
terms of reproducibility, we found that cyclin E expression was stable across multiple cohorts 
and subtypes of breast cancer. Hence, the expression of cytoplasmic cyclin E is not dependent on 
the state of differentiation of the disease, but instead is related to the aggressiveness of the 
disease.  
In terms of magnitude, cytoplasmic expression of cyclin E outperformed all other biomarkers 
examined in three of the four cohorts examined (MDA, NCI and UK), as shown in the stratified 
multivariate analysis with FFR as the endpoint (Table 3). To provide data for the clinical 
relevance of cyclin E as a prognostic marker, we interrogated if cyclin E can outperform grade 
and Ki67 in the ER-positive breast cancer patients. We examined grade and the expression of 
Ki67 when available and compared to cyclin E and the results revealed that cyclin E can separate 
the freedom from survival plots much more significantly than Ki67. Additionally, cyclin E 
assessment can be readily performed in most pathology laboratories and readily interpreted by 
pathologists without the need for complex algorithms required for interpretation of multi-gene 
assays currently in use. The 21-gene recurrence score assay (Oncotype Dx, Genomic Health, 
Inc.) provides prognostic information for patients with early stage, estrogen receptor positive 
breast cancer46. It also provides predictive information with respect to chemotherapy benefit in 
patients with a high recurrence score47. Another multi-gene assay is the MammaPrint test 
(Agendia, Inc.) which measures expression of 70 genes and categorizes tumors in patients with 
early stage breast cancer into low risk and high risk groups48. This test is similar to the 21-gene 
recurrence score assay in that it provides both prognostic and predictive information but is 
applicable to both estrogen receptor positive and negative tumor types48.  Immunohistochemistry 
for localization of cyclin E provides prognostic information across all subtypes in both early 
stage and advanced stage breast cancer. In terms of biomarker utility, cytoplasmic cyclin E can 
be readily detected with immunohistochemistry. The same assay will allow detection and scoring 
of both nuclear and cytoplasmic cyclin E using a readily available antibody and standardized 
scoring. The results can be interpreted without requiring complex bioinformatics and it can 
identify patients who may benefit from alternative treatment strategies targeting cyclin E. 
LMW-E has greater affinity for CDK2 than does full-length cyclin E, and LMW-E is a 
target for CDK2 inhibitors. In HER-2-positive breast cancer cells expressing LMW-E, the 
combination of targeting HER-2 with trastuzumab and targeting LMW-E with roscovitine led to 
synergistic killing.49 We propose that LMW-E not only is a prognostic marker but also could be 
useful as a predictive marker to identify patients who may benefit from LMW-E-targeted 
therapy. Previous studies of CDK inhibitors have not shown significant response rates, and 
therefore such inhibitors have been presumed to be ineffective. Measurement of cytoplasmic 
LMW-E may provide the best assessment of patients who could be treated effectively with 
LMW-E-targeted therapy. In our current study, patients with all breast cancer subtypes, 
including triple-negative breast cancer, had reduced recurrence-free survival when cytoplasmic 
cyclin E staining was detected. The lack of specific targets for triple-negative breast cancer is a 
major challenge, and LMW-E could be a target for this aggressive disease. 
The function of cytoplasmic cyclin E goes beyond cell proliferation. Historically, the 
function of nuclear cyclin E has been attributed to cell cycle progression, and overexpression of 
nuclear cyclin E leads to deregulation of cell proliferation. Cytoplasmic cyclin E, however, has 
alternate functions that can affect signal transduction 50, stemness 20,51, and metabolism 52, to list 
a few. In fact, comparing cytoplasmic cyclin E with Ki67 revealed that cyclin E was a more 
significant prognostic indicator than just increased cell proliferation (Supplemental Table 4 and 
Figure 3E and F). The non-cell cycle functions of cytoplasmic cyclin E also provide novel 
avenues for targeted treatment strategies for patients whose tumors express this protein.  For 
example, we recently identified ATP-citrate lyase (ACLY) as a novel interacting protein of 
LMW-E in the cytoplasm. LMW-E upregulates ACLY enzymatic activity and ACLY is required 
for LMW-E mediated transformation, migration and invasion in vitro, as well as tumor growth in 
vivo52).  These studies suggest a novel interplay between LMW-E and ACLY and provide an 
unexpected link between metabolic pathways and the cell cycle in breast cancer. Therefore, 
inhibition of ACLY and reduction of lipid accumulation may prove to be beneficial in targeting 
those breast cancers which display LMW-E expression  
In summary, cytoplasmic cyclin E expression can be readily assessed at diagnosis and is 
an important marker of prognosis and a target for therapy in breast cancer. Our finding that 
LMW-E as measured by immunohistochemistry is associated with poor outcomes provides a 
rationale for investigating treatment strategies that could specifically target tumors with LMW-E. 
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Figure Legends 
 
Figure 1.  Expression of low-molecular-weight cyclin E (LMW-E) in breast cancer.  (A) 
Correlation between Western blot analysis and immunohistochemical analysis for LMW-E.  
Tumor tissues from eight breast cancer patients were examined for cyclin E expression by 
Western blot analysis and immunohistochemistry with an antibody targeting the C-terminal 
epitope of the protein.  Cyclin E staining intensity and percent positivity were evaluated in both 
the nucleus and cytoplasm of invasive carcinoma cells and compared to the levels of full-length 
cyclin E and LMW-E measured by densitometry scanning of the corresponding bands on the 
Western blot.  Invasive breast cancer with undetectable or low levels of LMW-E showed a 
predominantly nuclear staining pattern (a-d), whereas invasive breast cancer with high levels of 
LMW-E demonstrated intense, homogeneous staining throughout the cytoplasm (e-h).  Table: 
Tumor tissues from 318 breast cancer patients from the Lab00-222 cohort were examined for 
cyclin E expression by western blot analysis and immunohistochemistry. Logistic regression was 
performed to assess if full-length and LMW-E occurrence on Western blot predict nuclear and 
cytoplasmic staining for cyclin E on immunohistochemistry, respectively. Statistical analysis 
revealed that the presence of full-length cyclin E and the presence of LMW-E on the Western 
blot were independent predictors of nuclear and cytoplasmic staining, respectively.  LMW, low 
molecular weight; N, normal; T, tumor. (B) Examples of the 4 different phenotypes of cyclin E 
staining:  no staining detected in the nucleus or cytoplasm (a), nuclear staining score exceeded 
cytoplasmic staining score (b), nuclear and cytoplasmic staining scores equal (c), and 
cytoplasmic staining score exceeding nuclear staining score (d).  C, cytoplasmic; N, nuclear.  
 
Figure 2.  Kaplan-Meier survival curves demonstrating the association between cyclin E 
phenotype and freedom from recurrence (FFR) survival in the three subtypes, HER2 positive, 
hormone receptor positive, and triple negative. A. Lab222; B. MDACC TMA; C. NCI; D. UK. 
Figure 3.  Nomograms for 5- and 10-year freedom from recurrence survival for patients in 
lab222 (A), MDACC TMA (B), NCI (C), and UK (D). The nomogram that corresponds to the 
Cox proportional hazards model with Ki67 in the MDACC TMA cohort (E). C-indices from 
models with/without cytoplasmic cyclin E (F).  
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Table 1. Clinical, pathologic, and treatment variables for the four patient cohorts* 
 
Variable 
No. of patients (%) 
P 
Combined 
cohort,  
n = 2494 
Lab00-222, 
n = 303 MDA, n = 725 NCI, n = 951 UK, n = 515 
Age       <0.0001 
Mean 61.1 yrs 57 yrs 54.1 yrs 59.6 yrs 76.2 yrs  
Median (range) 62 yrs (25-
96 yrs) 
57 yrs (26-
92 yrs) 
53 yrs (25-87 
yrs) 
60 yrs (25-
96 yrs) 
76 yrs (70-
91 yrs) 
 
<50 years 626 (25.1) 95 (31.4) 283 (39.0) 248 (26.1) 0 (0)  
50-75 years 1346 
(54.0) 
180 (59.4) 383 (52.8) 577 (60.7) 205 (39.8)  
≥75 years 523 (21) 28 (9.2) 59 (8.1) 126 (13.2) 310 (60.2)  
T stage      <0.0001 
T1 1282 
(51.4) 
164 (54.1) 396 (54.6) 557 (58.6) 165 (32.0)  
T2 1182 
(47.4) 
115 (38) 329 (45.4) 394 (41.4) 344 (66.8)  
T3 22 (0.9) 22 (7.3) 0 (0) 0 (0) 0 (0)  
NA 8 (0.3) 2 (0.7) 0 (0) 0 (0) 6 (1.2)  
Nodal status      <0.0001 
Negative 1527 
(61.2) 
173 (57.1) 426 (58.8) 546 (57.4) 382 (74.2)  
Positive 952 (38.2) 130 (42.9) 298 (41.1) 391 (41.1) 133 (25.8)  
Unknown 15 (0.6) 0 (0) 1 (0.1) 14 (1.5) 0 (0)  
Tumor grade       
I 374 (15.0) 30 (9.9) 63 (8.7) 230 (24.2) 51 (9.9) <0.0001 
II 1155 
(46.3) 
162 (53.5) 381 (52.6) 444 (46.7) 168 (32.6)  
III 861 (34.5) 110 (36.3) 270 (37.2) 277 (29.1) 204 (39.6)  
Unknown 104 (4.2) 1 (0.3) 11 (1.5) 0 (0) 92 (17.9)  
Subtype      0.0003 
 HER2-positive  362 (14.5) 44 (14.5) 126 (17.4) 134 (14.1) 58 (11.3)  
Hormone 
receptor-
positive 
1640 
(65.8) 
217 (71.6) 451 (62.2) 660 (69.4) 312 (60.6)  
Triple-negative 428 (17.2) 39 (12.9) 148 (20.4) 140 (14.7) 101 (19.6)  
Unknown 64 (2.6) 3 (1.0) 0 (0) 17 (1.8) 44 (8.5)  
Chemotherapy      <0.0001 
No 1661 
(66.6) 
142 (46.9) 383 (52.8) 621 (65.3) 515 (100)  
Yes 833 (33.4) 161 (53.1) 342 (47.2) 330 (34.7) 0 (0)  
Radiation therapy      <0.0001 
No 1613 
(64.7) 
135 (44.6) 421 (58.1) 638 (67.1) 419 (81.4)  
Yes 881 (35.3) 168 (55.4) 304 (41.9) 313 (32.9) 96 (18.6)  
Endocrine therapy      <0.0001 
No 1356 
(54.4) 
70 (23.1) 412 (56.8) 592 (62.3) 282 (54.8)  
Yes 1138 
(45.6) 
233 (76.9) 313 (43.2) 359 (37.7) 233 (45.2)  
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Ki67      <0.0001 
Mean 17.8% 12.7% 19.3%    
Median (range) 15% (0-
90%) 
10% (1-70%) 15% (0-90%)    
Unknown 1592 
(63.8) 
105 (34.7) 21 (2.9) 951 (100) 515 (100)  
Cytoplasmic cyclin 
E staining 
     0.4196 
Negative 981 (39.3) 116 (38.3) 298 (41.1) 357 (37.5) 210 (40.8)  
Positive 1513 
(60.7) 
187 (61.7) 427 (58.9) 594 (62.5) 305 (59.2)  
*P values were calculated using one-way analysis of variance for Ki67 and chi-square tests for 
categorical variables. 
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Table 2. Univariable Cox regression analyses for freedom from recurrence (FFR) in the Lab00-
222 (n = 303), MDA (n = 725), NCI (n = 951), UK (n = 515). 
  Lab00-222 MDA NCI UK 
  HR P HR P HR P HR P 
Age  
  
    
    <50 Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 50-75 0.62 0.1393 0.59 0.0004 0.74 0.0195 0.88 0.4719 
>=75 0.82 0.7455 0.45 0.0282 0.68 0.0816 
  T stage 
        T1 Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 T2 1.62 0.1854 2.17 <0.0001 3.07 <0.0001 1.25 0.252 
T3 9.56 <0.0001 
      Nodal status 
        Negative Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 Positive 2.61 0.0031 1.94 <0.0001 3.16 <0.0001 1.41 0.0686 
Tumor grade 
        I Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 II 0.98 0.9708 0.83 0.4954 1.63 0.0058 0.8 0.5425 
III 2.41 0.1535 1.27 0.3651 2.76 <0.0001 1.77 0.0842 
Subtype 
         HER2 positive Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 Hormone receptor 
positive 0.53 0.1079 0.61 0.0066 0.58 
7.00E-
04 0.64 0.1044 
Triple negative 1.76 0.2083 0.94 0.7838 1.13 0.5372 1.31 0.3601 
Chemotherapy 
        no Ref. 
 
Ref. 
 
Ref. 
   yes 0.75 0.3512 1.5 0.0062 2.29 <0.0001 
  Radiation therapy 
        no Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 yes 1.1 0.7625 1.01 0.9503 1.09 0.4917 0.9 0.6731 
Endocrine therapy 
        no Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 yes 0.41 0.0049 0.5 <0.0001 1.15 0.2544 0.52 0.0004 
Cytoplasmic cyclin E 
        Negative Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 Positive 4.16 0.0013 3.19 <0.0001 4.16 <0.0001 5.01 <0.0001 
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Table 3. Multivariable Cox regression analyses for freedom from recurrence (FFR) in the 
Lab00-222 (n = 303), MDA (n = 725), NCI (n = 951), UK (n = 515). 
  Lab00-222 MDA NCI UK 
  HR P HR P HR P HR P 
Age  
  
    
    <50 
  
Ref. 
   
Ref. 
 50-75 
  
0.66 0.0104 
  
0.72 0.1303 
>=75 
  
0.48 0.0595 
    T stage 
        T1 Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 T2 0.93 0.874 1.84 <0.0001 1.84 <0.0001 1.76 0.025 
T3 10.3 <0.0001 
      Nodal status 
        Negative Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 Positive 2.15 0.045 1.88 <0.0001 2.06 <0.0001 2.33 0.0003 
Tumor grade 
        I 
    
Ref. 
   II 
    
1.32 0.1518 
  III 
    
1.1.52 0.0742 
  Subtype 
         HER2 positive Ref. 
       Hormone receptor 
positive 0.43 0.056 
      Triple negative 1.62 0.319 
      Chemotherapy 
        no Ref. 
 
Ref. 
 
Ref. 
   yes 0.49 0.033 0.76 0.1109 1.24 0.115 
  Radiation therapy 
        no 
        yes 
        Endocrine therapy 
        no 
  
Ref. 
   
Ref. 
 yes 
  
0.61 0.0041 
  
0.47 0.001 
Cytoplasmic cyclin E 
        Negative Ref. 
 
Ref. 
 
Ref. 
 
Ref. 
 Positive 3.19 0.012 2.48 <0.0001 3.26 <0.0001 6.58 <0.0001 
 
 
 
